




PHARMACEUTICAL 2021

Amneal Pharmaceuticals Inc.
Rank 279 of 402





RealRate

PHARMACEUTICAL 2021

Amneal Pharmaceuticals Inc.
Rank 279 of 402



The relative strengths and weaknesses of Amneal Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Amneal Pharmaceuticals Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 77% points. The greatest weakness of Amneal Pharmaceuticals Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 177% points.

The company's Economic Capital Ratio, given in the ranking table, is 18%, being 30% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	1,551,539
Cost of Goods Sold	1,329,551
Intangible Assets	1,827,440
Liabilities, Current	676,902
Liabilities, Non-Current	2,972,395
Other Assets	149,300
Other Compr. Net Income	-18,722
Other Expenses	-45,058
Other Liabilities	0
Other Net Income	-132,795
Other Revenues	1,992,523
Property and Equipment	477,754
Research and Development	179,930
Selling, General and Administrative Expense	326,727

Output Variable	Value in 1000 USD
Assets	4,006,033
Liabilities	3,649,297
Expenses	1,791,150
Revenues	1,992,523
Stockholders Equity	356,736
Net Income	68,578
Comprehensive Net Income	59,217
Economic Capital Ratio	18%